EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 5

Ensembl ID : ENSELUG00000005574
Gene Symbol: CACNG5
3 Cross references
172 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6

Ensembl ID : ENSELUG00000015801
Gene Symbol: CACNG6
3 Cross references
177 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSELUG00000015707
Gene Symbol: CACNG7
3 Cross references
190 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSELUG00000001575
Gene Symbol: CACNG8
3 Cross references
163 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSELUG00000004264
Gene Symbol: CACNA1A
1 Cross references
198 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSELUG00000001559
Gene Symbol: CACNA1B
1 Cross references
215 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSELUG00000012946
Gene Symbol: CACNA1D
2 Cross references
209 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSELUG00000021389
Gene Symbol: CACNA1E
1 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSELUG00000008744
Gene Symbol: CACNA1E
1 Cross references
216 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSELUG00000023718
Gene Symbol: CACNA1G
3 Cross references
197 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSELUG00000031407
Gene Symbol: CACNA1H
1 Cross references
211 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSELUG00000020162
Gene Symbol: CACNA1I
1 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).